Evidence map›Paper›PMID 29709038›Full record

ArticlePLoS pathogens2018

HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition.

Nicolas Jouand, Céline Bressollette-Bodin, Nathalie Gérard, Magali Giral, Pierrick Guérif, Audrey Rodallec, Romain Oger, Tiphaine Parrot, Mathilde Allard, Anne Cesbron-Gautier and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Unconventional CD8Science advances · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. CD8Science advances · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Human CD8Immune network · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Nicolas JouandCentre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France.ORCID 0000-0003-4967-5909
Céline Bressollette-BodinCentre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France.ORCID 0000-0001-5175-0790
Nathalie GérardCentre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France.
Magali GiralCentre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France.
Pierrick GuérifInstitut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Audrey RodallecLaboratoire de Virologie, CHU Nantes, Nantes, France.
Romain OgerCRCINA, UMR1232, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Tiphaine ParrotCRCINA, UMR1232, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Mathilde AllardCRCINA, UMR1232, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Anne Cesbron-GautierEtablissement Français du Sang (EFS), Région des Pays de la Loire, Nantes, France.
Nadine GervoisCRCINA, UMR1232, INSERM, Université d'Angers, Université de Nantes, Nantes, France.ORCID 0000-0002-0092-3919
Béatrice CharreauCentre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France.ORCID 0000-0001-5870-4615
Inserm · FRÉtablissement Français du Sang · FRInstitut de Transplantation Urologie en Nephrologie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune response against human cytomegalovirus (HCMV) includes a set of persistent cytotoxic NK and CD8 T cells devoted to eliminate infected cells and to prevent reactivation. CD8 T cells against HCMV antigens (pp65, IE1) presented by HLA class-I molecules are well characterized and they associate with efficient virus control. HLA-E-restricted CD8 T cells targeting HCMV UL40 signal peptides (HLA-EUL40) have recently emerged as a non-conventional T-cell response also observed in some hosts. The occurrence, specificity and features of HLA-EUL40 CD8 T-cell responses remain mostly unknown. Here, we detected and quantified these responses in blood samples from healthy blood donors (n = 25) and kidney transplant recipients (n = 121) and we investigated the biological determinants involved in their occurrence. Longitudinal and phenotype ex vivo analyses were performed in comparison to HLA-A*02/pp65-specific CD8 T cells. Using a set of 11 HLA-E/UL40 peptide tetramers we demonstrated the presence of HLA-EUL40 CD8 αβT cells in up to 32% of seropositive HCMV+ hosts that may represent up to 38% of total circulating CD8 T-cells at a time point suggesting a strong expansion post-infection. Host's HLA-A*02 allele, HLA-E *01:01/*01:03 genotype and sequence of the UL40 peptide from the infecting strain are major factors affecting the incidence of HLA-EUL40 CD8 T cells. These cells are effector memory CD8 (CD45RAhighROlow, CCR7-, CD27-, CD28-) characterized by a low level of PD-1 expression. HLA-EUL40 responses appear early post-infection and display a broad, unbiased, Vβ repertoire. Although induced in HCMV strain-dependent, UL4015-23-specific manner, HLA-EUL40 CD8 T cells are reactive toward a broader set of nonapeptides varying in 1-3 residues including most HLA-I signal peptides. Thus, HCMV induces strong and life-long lasting HLA-EUL40 CD8 T cells with potential allogeneic or/and autologous reactivity that take place selectively in at least a third of infections according to virus strain and host HLA concordance.

Indexed as

Kidney TransplantationAdultAgedAntigen PresentationCase-Control StudiesCD8-Positive T-LymphocytesCells, CulturedCytomegalovirusCytomegalovirus InfectionsFemaleHistocompatibility Antigens Class IHLA-E AntigensHumansMaleMiddle AgedPeptide FragmentsHistocompatibility Antigens Class IHLA-E AntigensPeptide FragmentsUL40 glycoprotein, CytomegalovirusViral Proteins

Identifiers

PMID29709038
PMCPMC5945056
OpenAlexW2802657422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.